EGRX - Investigation Alert: Aldeyra Eagle Pharmaceuticals and Blue Ridge Bankshares: Johnson Fistel LLP Encourages Long-Term Investors to Submit Their Information Below | Benzinga
SAN DIEGO, June 13, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations of federal and state laws by certain officers of the companies of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), and Blue Ridge Bankshares, Inc. (NYSE:BRBS).
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)
Johnson Fistel, LLP is investigating potential claims on behalf of Aldeyra Therapeutics, Inc. against certain of its officers and directors.
If you are a current, long-term shareholder of Aldeyra holding shares before March 17, 2022, you may have standing to hold Aldeyra harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action:
https://www.cognitoforms.com/JohnsonFistel/AldeyraTherapeuticsInc
Recently a class action lawsuit was filed against the company. The lawsuit alleges Aldeyra made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and compliance policies, including: (i) the ADX-2191 new drug application ("NDA") did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve ...